The stock of Predictive Oncology Inc (NASDAQ: POAI) has decreased by -9.70 when compared to last closing price of 1.34.Despite this, the company has seen a loss of -11.03% in its stock price over the last five trading days. globenewswire.com reported 2025-01-16 that Initial plans target European clinical trials while providing standard testing to clinicians for individual patients There are an estimated 250,000 gynecologic cancers diagnosed annually across Europe PITTSBURGH, Jan. 16, 2025 (GLOBE NEWSWIRE) — Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, today announced plans to launch its validated flagship live cell ChemoFx® drug response assay in Europe and expanded availability in the United States. The ChemoFx® treatment selection marker and tumor profiling assay will initially focus on ovarian and other gynecological cancers and may include testing of other major tumor types of interest over time.
Is It Worth Investing in Predictive Oncology Inc (NASDAQ: POAI) Right Now?
Additionally, the 36-month beta value for POAI is 1.17. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for POAI is 6.52M and currently, short sellers hold a 2.17% ratio of that float. The average trading volume of POAI on January 20, 2025 was 1.16M shares.
POAI’s Market Performance
POAI stock saw an increase of -11.03% in the past week, with a monthly gain of 61.33% and a quarterly increase of 103.29%. The volatility ratio for the week is 13.55%, and the volatility levels for the last 30 days are 23.80% for Predictive Oncology Inc (POAI). The simple moving average for the past 20 days is 11.23% for POAI’s stock, with a 11.83% simple moving average for the past 200 days.
Analysts’ Opinion of POAI
Many brokerage firms have already submitted their reports for POAI stocks, with H.C. Wainwright repeating the rating for POAI by listing it as a “Buy.” The predicted price for POAI in the upcoming period, according to H.C. Wainwright is $3 based on the research report published on August 19, 2024 of the previous year 2024.
POAI Trading at 35.80% from the 50-Day Moving Average
After a stumble in the market that brought POAI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -67.82% of loss for the given period.
Volatility was left at 23.80%, however, over the last 30 days, the volatility rate increased by 13.55%, as shares surge +66.92% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +77.58% upper at present.
During the last 5 trading sessions, POAI fell by -11.03%, which changed the moving average for the period of 200-days by -40.98% in comparison to the 20-day moving average, which settled at $1.0878. In addition, Predictive Oncology Inc saw 47.56% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for POAI
Current profitability levels for the company are sitting at:
- -9.58 for the present operating margin
- 0.08 for the gross margin
The net margin for Predictive Oncology Inc stands at -10.13. The total capital return value is set at -3.59. Equity return is now at value -193.25, with -102.54 for asset returns.
Based on Predictive Oncology Inc (POAI), the company’s capital structure generated 0.55 points at debt to capital in total, while cash flow to debt ratio is standing at -5.0.
Currently, EBITDA for the company is -13.18 million with net debt to EBITDA at 0.05. When we switch over and look at the enterprise to sales, we see a ratio of 5.36. The receivables turnover for the company is 2.97for trailing twelve months and the total asset turnover is 0.18. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.20.
Conclusion
In conclusion, Predictive Oncology Inc (POAI) has seen mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
